BioMarin Pharmaceuticals BMRN Common Stock Held in Trust
Common Stock Held in Trust at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockIssuedEmployeeStockTrust.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's common stock held in trust.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's common stock held in trust?
- BioMarin Pharmaceuticals (BMRN) reported common stock held in trust of $10.45M in Q1 2026.
- How has BioMarin Pharmaceuticals's common stock held in trust changed year-over-year?
- BioMarin Pharmaceuticals's common stock held in trust decreased by 6.5% year-over-year, from $11.18M to $10.45M.
- What is the long-term trend for BioMarin Pharmaceuticals's common stock held in trust?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's common stock held in trust has grown at a 1.3% compound annual growth rate (CAGR), from $9.84M to $10.51M.
- What does common stock held in trust mean?
- Common shares set aside in a trust specifically for employee benefit and compensation plans.
- How do you interpret common stock held in trust?
- An increase suggests higher future dilution from equity compensation, while a decrease may indicate shares have been issued or the trust has been liquidated.
- How does common stock held in trust compare across companies?
- Common across biotech firms using equity-based compensation to attract talent; peers often report this within equity or as treasury stock.